Logo image of CLPT

CLEARPOINT NEURO INC (CLPT) Stock Fundamental Analysis

USA - NASDAQ:CLPT - US18507C1036 - Common Stock

19.28 USD
+7.12 (+58.55%)
Last: 9/24/2025, 8:00:00 PM
20.56 USD
+1.28 (+6.64%)
After Hours: 9/24/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, CLPT scores 3 out of 10 in our fundamental rating. CLPT was compared to 190 industry peers in the Health Care Equipment & Supplies industry. The financial health of CLPT is average, but there are quite some concerns on its profitability. CLPT is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CLPT has reported negative net income.
CLPT had a negative operating cash flow in the past year.
CLPT had negative earnings in each of the past 5 years.
In the past 5 years CLPT always reported negative operating cash flow.
CLPT Yearly Net Income VS EBIT VS OCF VS FCFCLPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M

1.2 Ratios

The Return On Assets of CLPT (-35.35%) is comparable to the rest of the industry.
The Return On Equity of CLPT (-112.56%) is worse than 65.79% of its industry peers.
Industry RankSector Rank
ROA -35.35%
ROE -112.56%
ROIC N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
CLPT Yearly ROA, ROE, ROICCLPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 1K

1.3 Margins

CLPT has a better Gross Margin (60.42%) than 61.05% of its industry peers.
In the last couple of years the Gross Margin of CLPT has declined.
The Profit Margin and Operating Margin are not available for CLPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 60.42%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
CLPT Yearly Profit, Operating, Gross MarginsCLPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

4

2. Health

2.1 Basic Checks

CLPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
CLPT has more shares outstanding than it did 1 year ago.
CLPT has more shares outstanding than it did 5 years ago.
CLPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLPT Yearly Shares OutstandingCLPT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
CLPT Yearly Total Debt VS Total AssetsCLPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

Based on the Altman-Z score of 0.52, we must say that CLPT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CLPT (0.52) is comparable to the rest of the industry.
A Debt/Equity ratio of 1.46 is on the high side and indicates that CLPT has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 1.46, CLPT is doing worse than 82.11% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Altman-Z 0.52
ROIC/WACCN/A
WACC8.75%
CLPT Yearly LT Debt VS Equity VS FCFCLPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M

2.3 Liquidity

CLPT has a Current Ratio of 7.30. This indicates that CLPT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 7.30, CLPT belongs to the top of the industry, outperforming 87.37% of the companies in the same industry.
A Quick Ratio of 6.45 indicates that CLPT has no problem at all paying its short term obligations.
CLPT has a better Quick ratio (6.45) than 87.37% of its industry peers.
Industry RankSector Rank
Current Ratio 7.3
Quick Ratio 6.45
CLPT Yearly Current Assets VS Current LiabilitesCLPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for CLPT have decreased strongly by -14.08% in the last year.
CLPT shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.69%.
The Revenue has been growing by 22.85% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-14.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.25%
Revenue 1Y (TTM)19.69%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%17.27%

3.2 Future

CLPT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.12% yearly.
The Revenue is expected to grow by 32.35% on average over the next years. This is a very strong growth
EPS Next Y-17.3%
EPS Next 2Y0.82%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue Next Year18.26%
Revenue Next 2Y21.83%
Revenue Next 3Y32.35%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CLPT Yearly Revenue VS EstimatesCLPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2030 2031 2032 50M 100M 150M 200M
CLPT Yearly EPS VS EstimatesCLPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2020 2021 2022 2023 2024 2025 2026 2027 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CLPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLPT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLPT Price Earnings VS Forward Price EarningsCLPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLPT Per share dataCLPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y0.82%
EPS Next 3Y3.12%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLPT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLEARPOINT NEURO INC

NASDAQ:CLPT (9/24/2025, 8:00:00 PM)

After market: 20.56 +1.28 (+6.64%)

19.28

+7.12 (+58.55%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-05 2025-11-05
Inst Owners35.26%
Inst Owner Change15.8%
Ins Owners5.24%
Ins Owner Change12.74%
Market Cap548.13M
Analysts82.5
Price Target29.58 (53.42%)
Short Float %9.01%
Short Ratio6.66
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-18.87%
Min EPS beat(2)-34.8%
Max EPS beat(2)-2.94%
EPS beat(4)0
Avg EPS beat(4)-14.9%
Min EPS beat(4)-34.8%
Max EPS beat(4)-1.81%
EPS beat(8)4
Avg EPS beat(8)1%
EPS beat(12)6
Avg EPS beat(12)-2.43%
EPS beat(16)8
Avg EPS beat(16)-1.42%
Revenue beat(2)1
Avg Revenue beat(2)-0.18%
Min Revenue beat(2)-1.8%
Max Revenue beat(2)1.45%
Revenue beat(4)2
Avg Revenue beat(4)-1.35%
Min Revenue beat(4)-7.42%
Max Revenue beat(4)2.36%
Revenue beat(8)5
Avg Revenue beat(8)-0.89%
Revenue beat(12)6
Avg Revenue beat(12)-1.07%
Revenue beat(16)9
Avg Revenue beat(16)0.93%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.11%
EPS NY rev (1m)0%
EPS NY rev (3m)-5%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.31%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.32
P/FCF N/A
P/OCF N/A
P/B 27.76
P/tB 27.76
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.69
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)-0.39
OCFYN/A
SpS1.18
BVpS0.69
TBVpS0.69
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -35.35%
ROE -112.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 60.42%
FCFM N/A
ROA(3y)-43.22%
ROA(5y)-34.92%
ROE(3y)-74.46%
ROE(5y)-107.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.19%
GM growth 5Y-1.52%
F-Score4
Asset Turnover0.53
Health
Industry RankSector Rank
Debt/Equity 1.46
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 54.74%
Cap/Sales 1.63%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.3
Quick Ratio 6.45
Altman-Z 0.52
F-Score4
WACC8.75%
ROIC/WACCN/A
Cap/Depr(3y)225.04%
Cap/Depr(5y)185.37%
Cap/Sales(3y)3.62%
Cap/Sales(5y)3.13%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-31.25%
EPS Next Y-17.3%
EPS Next 2Y0.82%
EPS Next 3Y3.12%
EPS Next 5YN/A
Revenue 1Y (TTM)19.69%
Revenue growth 3Y24.41%
Revenue growth 5Y22.85%
Sales Q2Q%17.27%
Revenue Next Year18.26%
Revenue Next 2Y21.83%
Revenue Next 3Y32.35%
Revenue Next 5YN/A
EBIT growth 1Y-21.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year31.89%
EBIT Next 3Y25.55%
EBIT Next 5YN/A
FCF growth 1Y38.98%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y36.84%
OCF growth 3YN/A
OCF growth 5YN/A